NASDAQ · GLMD
Healthcare · Biotechnology
$0.53
Down-$0.03 (-5.18%)
Updated Aug 14, 2026, 10:43 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
GLMD closed at $0.53 after 21 trading sessions, down 3.47% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $0.541 | $0.5683 | $0.53 | $0.531 | 29.15K |
| Aug 12, 2026 | $0.5569 | $0.5816 | $0.53 | $0.56 | 117.09K |
| Aug 11, 2026 | $0.5701 | $0.575 | $0.5501 | $0.5569 | 29.52K |
| Aug 10, 2026 | $0.598 | $0.60 | $0.5805 | $0.5931 | 14.65K |
| Aug 7, 2026 | $0.5741 | $0.6019 | $0.5729 | $0.6019 | 21.98K |
| Aug 6, 2026 | $0.5696 | $0.60 | $0.56 | $0.599 | 13.47K |
| Aug 5, 2026 | $0.5642 | $0.58 | $0.5601 | $0.58 | 24.02K |
| Aug 4, 2026 | $0.57 | $0.5755 | $0.5602 | $0.5754 | 44.24K |
| Aug 3, 2026 | $0.6132 | $0.6132 | $0.5753 | $0.585 | 72.84K |
| Jul 31, 2026 | $0.6042 | $0.621 | $0.5405 | $0.621 | 140.89K |
| Jul 30, 2026 | $0.5409 | $0.599 | $0.53 | $0.599 | 107.97K |
| Jul 29, 2026 | $0.5311 | $0.56 | $0.51 | $0.5597 | 87.13K |
| Jul 28, 2026 | $0.529 | $0.6193 | $0.492 | $0.534 | 3.24M |
| Jul 27, 2026 | $0.5026 | $0.547 | $0.5026 | $0.527 | 60.58K |
| Jul 24, 2026 | $0.55 | $0.55 | $0.51 | $0.5129 | 22.07K |
| Jul 23, 2026 | $0.48 | $0.5584 | $0.4735 | $0.553 | 209.95K |
| Jul 22, 2026 | $0.5189 | $0.519 | $0.4569 | $0.5049 | 327.66K |
| Jul 21, 2026 | $0.496 | $0.5195 | $0.496 | $0.519 | 77.95K |
| Jul 20, 2026 | $0.5295 | $0.55 | $0.465 | $0.5146 | 180.97K |
| Jul 17, 2026 | $0.5322 | $0.5888 | $0.52 | $0.5459 | 320.05K |
| Jul 16, 2026 | $0.5454 | $0.587 | $0.4578 | $0.5501 | 14.15M |
The latest Smart Investors Daily articles mentioning GLMD.
GLMD research
Company profile and research snapshot.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 4, 2025 | Maxim Group | Hold | — |
| Jul 24, 2023 | Maxim Group | Buy | — |
| Aug 8, 2022 | Maxim Group | Hold | — |
| Aug 8, 2022 | Canaccord Genuity | Hold | — |
| May 18, 2022 | Raymond James | Market Perform | — |
No generated briefing is available yet.
Benzinga · Jul 28, 2026
Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration.In order to improve patient convenience and long-term treatment adherence by
Benzinga · Jul 16, 2026
Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution
Benzinga · Jul 1, 2026
https://x.com/PatentGrants/status/2072409116040130916 https://patentcenter.uspto.gov/applications/17863472/ifw/docs
Yahoo · Jun 22, 2026
Galmed today announces that following a restructuring of the acquisition terms, it consummated the acquisition of Colospan a commercial-stage medical device company that has developed a clinically differentiated solution to one of colorectal surgery's most pressing problems: anastomotic leak complications and the diverting stomas used to manage them.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GLMD.
